Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436640 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
A Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
- 20
- Study locations
NCT04436640: Active Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL.
NCT04436640 is a Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 508 participants, below the 38,163-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04436640, a Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (20)
Other
- As0014 40004 - Brussels
- As0014 40003 - Genk
- As0014 40001 - Ghent
- As0014 40006 - Plovdiv
- As0014 40007 - Plovdiv
- As0014 40005 - Sofia
- As0014 40008 - Sofia
- As0014 20040 - Beijing
- As0014 20021 - Chengdu
- As0014 20019 - Guangzhou
Arizona
- As0014 50062 - Glendale
- As0014 50052 - Phoenix
Florida
- As0014 50059 - Ormond Beach
- As0014 50056 - Sarasota
California
- As0014 50060 - Upland
Maryland
- As0014 50015 - Hagerstown
Missouri
- As0014 50016 - St Louis
Oregon
- As0014 50055 - Portland
Pennsylvania
- As0014 50020 - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2026-08-07 |
| Phase | Phase 3 |
What the registry record for NCT04436640 still lists
NCT04436640 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, below the 38,163-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Ankylosing Spondylitis appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT04436640 names 20 study sites across 9 states, led by Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04436640 about?
NCT04436640 is a clinical study titled "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis". The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
What is the current status of trial NCT04436640?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2020-06-16. Estimated completion is 2026-08-07.
What conditions does trial NCT04436640 study?
This clinical trial studies the following conditions: Ankylosing Spondylitis, Axial Spondyloarthritis, r-axSpa, Nr-axSpa.
What interventions are being tested in trial NCT04436640?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04436640?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04436640 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ankylosing Spondylitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04436640's enrollment target sits among peer trials
508 8th of 15 higher than 8 of 15 other Ankylosing Spondylitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ankylosing Spondylitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
COMPLETED · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI